Preclinical in vivo validation of a glioblastoma neuro snooper electrical device

ended

Median survival for people that are diagnosed with glioblastoma (GBM) is only 15 months. Chemoradiotherapy and targeted therapies still fail to combat peritumoral relapse after tumour removal. Preventing peritumoral brain invasion is the main target to cure GBM. Our project aims to validate a proof-of concept for a new medical device (MD) ‘GBM Neuro Snooper’ in GBM animal models, a required step before initiating a clinical trial (Technology Readiness Level from 2/3 to 4). This MD will allow to define an in-situ electrophysiology profile of patients with GBM, after the tumor resection, to access a new mechanistic understanding in the brain tumour field as well as, new strategies for patient stratification and treatment. Already existing MDs with electrode wires are either very stiff or with a millimetric dimension. The ERC work will lead to a first generic, miniaturised prototype implant with moderate invasiveness and which design was validated in connection with neurosurgeons for the GBM application, validation of its Freedom to Operate in the context of continuous IP landscaping and the creation of an exploitation plan. In a long-term perspective, it will help characterise hyperexcitability in brain diseases such as tumors, but also epilepsy or the Alzheimer Disease. We will also investigate the effect of stimulation of the peritumoral tissue and the correlation with the recorded signals as a new electro-theragnostic strategy. We will address the ethics and social dimension of using such a MD and our exploitation plan will include the protection of intellectual property, business strategy and the preparation of a clinical trial after project completion. The project will be performed by a dedicated team that includes significant expertise in technical development, preclinical validation of devices, surgery, and knowledge transfer.